2 Drug Stocks Gapping Lower Today

Apple may be dropping Qualcomm for Intel

by Patrick Martin

Published on Feb 5, 2018 at 2:33 PM
Updated on Feb 5, 2018 at 2:37 PM

U.S. stocks continue to sink, mired in their worst sell-off in over a year. Among the stocks making notable moves today are chip stock Intel Corporation (NASDAQ:INTC), as well as biotech stocks Prothena Corporation (NASDAQ:PRTA) and Corcept Therapeutics Incorporated (NASDAQ:CORT). Here's a closer look at what's moving shares of INTC, PRTA, and CORT today.

Apple Hopes Bolster INTC Stock

Intel stock is up 1.4% at $46.77, at last check -- among the few Dow stocks higher in afternoon trading -- lifted amid rumors Apple (AAPL) might dropping its chip supplier Qualcomm (QCOM) in favor of Intel. The speculation has INTC stock on track to snap a five-day losing streak. The security broke past the $50 mark last Friday for the first time since 2000, thanks to a well-received earnings report, and ultimately peaked at $50.85 on Monday. Since then, however, Intel shares have suffered with the broader equities market.

In the options pits, calls continue to be popular. At the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), INTC's 10-day call/put volume ratio sits at 2.86. Not only does this show that calls have outnumbered puts by a nearly 3-to-1 ratio, but this ratio ranks in the 70th percentile of its annual range. This indicates that traders have bought to open Intel calls over puts at a faster-than-usual clip lately.

Chief Medical Officer Departure Guts PRTA Stock

Late Friday, Prothena announced the resignation of its chief medical officer. The news has sent PRTA stock reeling, down 23% to trade at $30.39 -- and just off a nearly two-year low of $29.83. The biotech stock has now shed 56% since its September high of $70, and is currently short-sale restricted.

Analysts may be re-thinking their bullish stance on the equity, which is among the worst of the Nasdaq today. Of the nine brokerages covering PRTA, eight rate the shares a "buy" or "strong buy." Furthermore, PRTA's average 12-month price-target sits at $75.64, about a 150% premium from the stock's current perch. This indicates the biotech stock could be susceptible to downgrades and/or price-target cuts in the future. 

TEVA's NDA Letter Sends CORT Stock Spiraling

Shares of CORT are down a whopping 25% at $17.50, and are the worst of the Nasdaq so far, after Teva Pharmaceutical (TEVA) filed an abbreviated new drug application (NDA) for a generic version of Corcept's hyperglycemia treatment, Korlym. The news has CORT stock, which is currently short-sale restricted, testing its 160-day moving average for the second time since December. Nevertheless, CORT stock has added nearly 120% in the past 52-weeks, and touched a record high of $25.96 on Jan. 29.  

Although CORT stock is short-sale restricted, plenty of short sellers are likely cheering today's collapse. Short interest increased by 75% during the last two reporting periods, and has more than doubled since early November. These bearish bets now represent 18% of CORT's total available float.


a schaeffer's exclusive

5 NEW STOCK PICKS

We're celebrating 38 years with this FREE insider report!


 
 

Partnercenter


NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories


What's Next for the American Wealth Gap
Porter Stansberry is predicting a major change in the American economic system.
Oil Volatile in Choppy Week for Stocks
Oil had its best day in over a decade on Monday
2 Stocks Analysts Are Talking About Today
Bofa-Merrill Lynch downgraded Xilinx, while Etsy was upgraded at RBC
How the 2020 Election Will Affect the U.S. Economy
The 2020 election could see some major changes in the American economic system.